Sunday, 18 February 2018

Viscosupplementation to Replace Expensive Knee Surgeries

Rising cases of osteoarthritis owing to biomechanical, biochemical, and genetic factors are expected to increase the demand for viscosupplementation. The viscosupplementation procedure with hyaluronic acid is gaining popularity owing to its effective results in treating the symptoms of knee osteoarthritis. Increasing adoption of advanced therapeutic treatments can possibly reduce the number of patients.

Viscosupplementation

Demand for Single Injection Cycles to Remain High through 2025

Major product variants of viscosupplementation are single injection, three injection, and five injection. Single injection cycles are likely to dominate the market owing to increasing preference for shorter regimen. Synvisc-One (Sanofi) and Gel-One (Zimmer Holdings) are two convenient single injections and are easily available. To cater to the demand, most manufacturing companies are involved in R&D to create better products for consumers.

For instance, a U.S. based Orthopedics Company named Anika Therapeutics has recently declared its enrollment for second pivotal phase three trial evaluation of CINGAL. This product is likely to be the very first viscosupplement made from a combination of triamcinolone hexacetonide and hyaluronic acid. Triamcinolone hexacetonide is an FDA approved steroid used to treat inflammation. Hyaluronic acid is an active ingredient for viscosupplements such as monovisc and orthovisc. In this phase, the company will be evaluating around 576 patients who are suffering from osteoarthritis. Quality of life, effectiveness in improving pain, and functioning are a few factors, which will be considered during this evaluation.

Market Overview

According to a report by Grand View Research, Inc.; the viscosupplementation market is anticipated to reach 6.52 billion by 2025. Increasing disposable income and raising awareness about advanced healthcare procedures are likely to propel the growth of the market. High demand for minimally invasive treatments can augment the market growth in coming years. Continuous R&D and rapid advancements in technology are expected to contribute to the market growth during the forecast period (2017 to 2025).

Some of the top players in the market are AnikaTherapeutics, Inc.; Bioventus; Sanofi; Seikagaku Corporation; and Zimmer Holdings Inc.

In-Depth Research Report On Viscosupplementation Market:
https://www.grandviewresearch.com/industry-analysis/viscosupplementation-market

No comments:

Post a Comment

Ophthalmic Ultrasound Devices Market - Global Forecasts to 2026 by Grand View Research, Inc.

19-Mar-2020: The global ophthalmic ultrasound devices market size is expected to reach USD 728.7 million by 2026, according to a new repo...